Patent intelligence · US
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
Patent details — US 12396974
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 26, 2025
- Expiration
- Aug 21, 2045
- Applicant
- KetoneAid
- Claims
- 19
- CPC classes
- A61K, A61K31/047, A61K31/19, A61K31/22
Quick answer
US 12396974 (Ketone ester as a therapeutic treatment of Covid-19 and related viral infections) is held by KetoneAid. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KetoneAid
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/047, A61K31/19, A61K31/22, A61K31/23, A61K31/375
More from KetoneAid
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Frequently asked questions
What is US patent 12396974?
US 12396974 (Ketone ester as a therapeutic treatment of Covid-19 and related viral infections) is held by KetoneAid. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12396974?
KetoneAid is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 12396974 expire?
Our index shows an expiration date of Aug 21, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.